Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies

Annals of Medicine

Volumn 38, Issue 8, 2006, Pages 545-551

  Zhang, Wu ^a   Gordon, Michael ^a   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cetuximab; Colorectal cancer; Monoclonal antibodies; Panitumumab

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; IMMUNOGLOBULIN G1; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR;

ACNE; ADD ON THERAPY; ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GENE OVEREXPRESSION; HUMAN; HYPOMAGNESEMIA; INFUSION REACTION; INTERSTITIAL LUNG DISEASE; LOADING DRUG DOSE; MACULOPAPULAR RASH; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; SKIN TOXICITY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33847124958     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/09546630601070812     Document Type: Review

References (44)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-30.
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041-7.
3. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-14.
4. Kohne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol. 2005;23:4856-65.
5. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-45.
6. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002;94:1593-611.
7. Meyers MB, Biedler JL. Evidence for reverse transformation in multidrug-resistant human neuroblastoma cells. Prog Clin Biol Res. 1988;271:449-61.
8. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer. 1993;71:2454-60.
9. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183-232.
10. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol. 2002;20 Suppl:1S-13S.
11. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995;1:1311-8.
12. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol. 2001;19 Suppl:32S-40S.
13. Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1993;53:4322-8.
14. Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol. 2002;29 Suppl 14:38-44.
15. Bonner JA, Raisch KP, Trummell HQ, Robert F, Meredith RF, Spencer SA, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol. 2000;18 Suppl:47S-53S.
16. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res. 2002;8:994-1003.
17. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-8.
18. Lenz H-J, Mayer RJ, Mirtsching B, Cohn AL, Pippas A, Windt P, et al. Consistent Response to Treatment with Cetuximab Monotherapy in Patients with Metastatic Colorectal Cancer. J Clin Oncol, ASCO Annual Meeting Proceedings part I of II. 2005;23:Abstract 3536.
19. Abubakr Y, Eng C, Pautret V, Maurel J, Scheithauer W, Kroening H. Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC). J Clin Oncol, ASCO Annual Meeting Proceedings part I. 2006;24:Abstract 3556.
20. Folprecht G, Lutz MP, Schoffski P, Seufferlein T, Nolting A, Pollert P, et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol. 2006;17:450-6.
21. Rougier P, Raoul JL, Van Laethem J-L, Peeters M, Husseini F, Brezault C, et al. Cetuximab+FOLFIRI as firstline treatment for metastatic colorectal CA. J Clin Oncol, ASCO Annual Meeting Proceedings (Post Meeting Edition). 2004;22:Abstract 3513.
22. D?́az-Rubio E, Tabernero J, Van Cutsem E, Cervantes A, André T, Humblet Y, et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. J Clin Oncol, ASCO Annual Meeting Proceedings, part I of II. 2005;23:Abstract 3535.
23. Seufferlein T, Dittrich C, Riemann J, Woell E, Herrmann T, Lordick F, et al. A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings Part I of II. 2005;23:Abstract 3644.
24. Borner M, Mingrone W, Koeberle D, Von Moos R, Rauch D, Saletti P, et al. The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol, ASCO Annual Meeting Proceedings part I. 2006;24:Abstract 3551, 2006.
25. Saltz LB, Lenz HJ, Hochster H, Wadler S, Hoff P, Kemeny N, et al. Randomized Phase II Trial of Cetuximab/Bevacizumab/Irinotecan (CBI) versus Cetuximab/Bevacizumab (CB) in Irinotecan-Refractory Colorectal Cancer. J Clin Oncol, ASCO Annual Meeting Proceedings part I. 2005;23:Abstract 3508.
26. Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMCC225): superiority over single-agent receptor targeting. Clin Cancer Res. 2004;10:6487-501.
27. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144:1169-76.
28. Erbitux (Cetuximab) package insert, ImClone systems. NY, and Bristol-Myers Squibb, Princeton, NY; August 2005.
29. Lenz HJ, Mayer RJ, Gold PJ, Mirtsching B, Stella PJ, Cohn AL, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. J Clin Oncol, ASCO Annual Meeting Proceedings (Post Meeting Edition). 2004;22:Abstract 3510.
30. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23:1803-10.
31. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6:279-86.
32. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992-5.
33. Zhang W, Gordon M, Press OA, Rhodes K, Vallbohmer D, Yang DY, et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics. 2006;16:475-83.
34. Vallbohmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol. 2005;23:3536-44.
35. Bier H, Hoffmann T, Haas I, van Lierop A. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother. 1998;46:167-73.
36. Zhang W, Gordon M, Schultheis AM, Nagashima AM, Azuma M, Yang D, et al. Two immunoglobulin G fragment C receptor polymorphisms associated with clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with single agent cetuximab. J Clin Oncol, ASCO Annual Meeting Proceedings part I. 2006;24:Abstract 3028.
37. Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004;58:984-90.
38. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001;38:17-23.
39. Malik I, Hecht JR, Patnaik A, Venook A, Berlin J, Croghan G, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol, ASCO Annual Meeting Proceedings part I of II. 2005;23:Abstract 3520.
40. Hecht J, Mitchell E, Baranda J, Malik I, Richards D, Navale L, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. 2006;24:Abstract 3547.
41. Gibson TB, Ranganathan A, Grothey A. Randomized phase III trial results of panitumumab, a fully human antiepidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer. 2006;6:29-31.
42. Hecht J, Posey J, Tchekmedyian S, Hu E, Chan D, Malik I, et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIRI for first-line treatment of metastatic colorectal cancer (mCRC). J Clin Oncol, 2006 Gastrointestinal Cancers Symposium. 2006:Abstract 237.
43. Figlin RA, Belldegrun A, Crawford J, Lohner M, Roskos L, Yang XD, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. J Clin Oncol, 2002 ASCO Annual Meeting Proceedings. 2002;21:(Abstract 35).
44. Hecht JR, Patnaik A, Malik I, Venook A, Berlin J, Croghan G, et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post Meeting Edition). 2004;22:Abstract 3511.